Advanced Filters
noise

Metastatic Cancer Clinical Trials

A listing of Metastatic Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,209 clinical trials
B Binghe Xu, Doctor

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

This research study is evaluating the efficacy and safety of TSL-1502 capsules in patients with breast cancer, will be included HER2-negative locally advanced or metastatic breast cancer patients with germline BRCA mutations.

18 - 75 years of age Female Phase 2
C Carl Brown

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.

18 years of age All Phase 2
C Chaoqun Fei, M.D.

To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.

To investigate the real-world efficacy and safety of Sacituzumab govitecan for HER2 negative metastatic breast cancer patients in China.

18 - 75 years of age Female Phase N/A
B Bernadette Vertogen

Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.

18 years of age All Phase 2
J Juan Jin Attending physician

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

The study will be conducted as an open-label, single-center, Phase II clinical study, with a planned enrollment of 70 patients with locally advanced or metastatic HER2-positive and HER2-low breast cancer who are intended to receive at least two cycles of T-DXd monotherapy. All patients receiving T-DXd treatment must meet current …

18 years of age Female Phase N/A
S Susan S Cork

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan. Pluvicto is FDA-approved, but patients with super scan bone scans were previously …

18 years of age Male Phase 2
E Estefania Bobe Cortes

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

18 years of age All Phase 1/2
S Study Coordinator

Kisspeptin Administration Subcutaneously to Patients With IHH

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered …

18 years of age All Phase 2
N Niv Pencovich, MD, PhD, Professor

Safety of HRX215 in Patients After Minor and Major Liver Resection

The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: to learn about the safety and tolerability of HRX215 to learn about how the body absorbs, distributes, and gets …

18 - 75 years of age All Phase 1/2
B Bruno Toussaint, Dr

Clinical and Radiological Outcomes of Medacta Shoulder System FR

This is a post-marketing surveillance on Medacta Shoulder System

18 years of age All Phase N/A

Simplify language using AI